BEYONDSPRING INC.

(BYSI)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
1.520 USD   +0.66%
07/27NORTH AMERICAN MORNING BRIEFING : Growth Stocks -2-
DJ
07/13NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
06/29NORTH AMERICAN MORNING BRIEFING : Futures Waver -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 3000 Growth Index

06/24/2022 | 12:00am EDT

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 3000 Growth Index


© S&P Capital IQ 2022
All news about BEYONDSPRING INC.
07/27NORTH AMERICAN MORNING BRIEFING : Growth Stocks -2-
DJ
07/13NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
06/29NORTH AMERICAN MORNING BRIEFING : Futures Waver -2-
DJ
06/24BEYONDSPRING INC.(NASDAQCM : BYSI) dropped from Russell 3000 Growth Index
CI
06/24BEYONDSPRING INC.(NASDAQCM : BYSI) dropped from Russell 2000 Dynamic Index
CI
06/24BEYONDSPRING INC.(NASDAQCM : BYSI) dropped from Russell 2000 Index
CI
06/24BEYONDSPRING INC.(NASDAQCM : BYSI) dropped from Russell 2000 Growth Index
CI
06/24BEYONDSPRING INC.(NASDAQCM : BYSI) dropped from Russell Small Cap Comp Growth Index
CI
06/24BEYONDSPRING INC.(NASDAQCM : BYSI) dropped from Russell 3000E Index
CI
06/24BEYONDSPRING INC.(NASDAQCM : BYSI) dropped from Russell 3000E Growth Index
CI
More news
Analyst Recommendations on BEYONDSPRING INC.
More recommendations
Financials (USD)
Sales 2022 0,70 M - -
Net income 2022 -49,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,29x
Yield 2022 -
Capitalization 59,2 M 59,2 M -
Capi. / Sales 2022 84,5x
Capi. / Sales 2023 43,8x
Nbr of Employees 103
Free-Float 47,6%
Chart BEYONDSPRING INC.
Duration : Period :
BeyondSpring Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEYONDSPRING INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 1,52 $
Average target price 2,30 $
Spread / Average Target 51,3%
EPS Revisions
Managers and Directors
Lan Huang Chairman & Chief Executive Officer
Elizabeth Adkins Czerepak Chief Financial Officer
Ramon W. Mohanlal Director, Chief Medical Officer, Executive VP-R&D
G. Kenneth Lloyd Chief Scientific Officer
Matthew Kirkby Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BEYONDSPRING INC.-66.67%59
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-20.64%41 093